Cargando…

Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis

Objective To do an indirect comparison analysis of apixaban against dabigatran etexilate (2 doses) and rivaroxaban (1 dose), as well as of rivaroxaban against dabigatranetexilate (2 doses), for their relative efficacy and safety against each other, with particular focus on the secondary prevention p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rasmussen, Lars Hvilsted, Larsen, Torben Bjerregaard, Graungaard, Tina, Skjøth, Flemming, Lip, Gregory Y H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489505/ https://www.ncbi.nlm.nih.gov/pubmed/23129490 http://dx.doi.org/10.1136/bmj.e7097

Ejemplares similares

Non-Vitamin K Antagonist Oral Anticoagulants and the Treatment of Venous Thromboembolism in Cancer Patients: A Semi Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes
por: Larsen, Torben Bjerregaard, et al.
Publicado: (2014)

Stroke and mortality in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study
por: Lip, Gregory Y H, et al.
Publicado: (2012)

Bleeding Complications in Anticoagulated Patients With Atrial Fibrillation and Sepsis: A Propensity‐Weighted Cohort Study
por: Søgaard, Mette, et al.
Publicado: (2017)

Hematuria in anticoagulated patients with atrial fibrillation and urologic cancer
por: Ording, Anne Gulbech, et al.
Publicado: (2022)

Seasonality, incidence and prognosis in atrial fibrillation and stroke in Denmark and New Zealand
por: Christensen, Anette Luther, et al.
Publicado: (2012)

Vascular Disease and Risk Stratification for Ischemic Stroke and All-Cause Death in Heart Failure Patients without Diagnosed Atrial Fibrillation: A Nationwide Cohort Study
por: Melgaard, Line, et al.
Publicado: (2016)

Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants
por: Ording, Anne Gulbech, et al.
Publicado: (2021)

Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage
por: Nielsen, Peter Brønnum, et al.
Publicado: (2019)

Effectiveness and safety of self-managed oral anticoagulant therapy compared with direct oral anticoagulants in patients with atrial fibrillation
por: Grove, Erik Lerkevang, et al.
Publicado: (2018)

Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
por: Larsen, Torben Bjerregaard, et al.
Publicado: (2016)

Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study
por: Nielsen, Peter Brønnum, et al.
Publicado: (2016)

Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
por: Nielsen, Peter Brønnum, et al.
Publicado: (2017)

Nonvitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients and Risk of Dementia: A Nationwide Propensity‐Weighted Cohort Study
por: Søgaard, Mette, et al.
Publicado: (2019)

Cost Effectiveness of Patient Self-Managed Warfarin Compared with Direct Oral Anticoagulants in Atrial Fibrillation: An Economic Evaluation in a Danish Healthcare Sector Setting
por: Raunbak, Sabine Michelsen, et al.
Publicado: (2022)

Thromboembolic Risk in Patients With Pneumonia and New-Onset Atrial Fibrillation Not Receiving Anticoagulation Therapy
por: Søgaard, Mette, et al.
Publicado: (2022)

The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis
por: Vestergaard, Anne Sig, et al.
Publicado: (2017)

Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation
por: Diener, Hans-Christoph, et al.
Publicado: (2020)

Atrial fibrillation in patients with severe mental disorders and the risk of stroke, fatal thromboembolic events and bleeding: a nationwide cohort study
por: Søgaard, Mette, et al.
Publicado: (2017)

Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care
por: Lane, Deirdre A., et al.
Publicado: (2017)

Effectiveness and Safety of Direct Oral Anticoagulant for Secondary Prevention in Asians with Atrial Fibrillation
por: Park, Jiesuck, et al.
Publicado: (2019)

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
por: Turpie, Alexander GG
Publicado: (2014)

Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients
por: Schäfer, Andreas, et al.
Publicado: (2020)

Disparities in oral anticoagulation initiation in patients with schizophrenia and atrial fibrillation: A nationwide cohort study
por: Højen, Anette Arbjerg, et al.
Publicado: (2022)

Evaluation of Risk Scores as Predictive Tools for Stroke in Patients with Retinal Artery Occlusion: A Danish Nationwide Cohort Study
por: Ørskov, Marie, et al.
Publicado: (2022)

Stroke Prevention in Atrial Fibrillation: Concepts and Controversies
por: Ahmad, Yousif, et al.
Publicado: (2012)

Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention
por: Zulkifly, Hanis, et al.
Publicado: (2022)

Emerging Tools for Stroke Prevention in Atrial Fibrillation
por: Voukalis, Christos, et al.
Publicado: (2016)

Risk of stroke and bleeding in patients with heart failure and chronic kidney disease: a nationwide cohort study
por: Melgaard, Line, et al.
Publicado: (2018)

Stroke Prevention in Atrial Fibrillation: Where are We Now?
por: Ahmad, Yousif, et al.
Publicado: (2012)

Preventing stroke in atrial fibrillation patients – clinical utility of oral anticoagulants
por: Jhawar, Manish B, et al.
Publicado: (2012)

Percutaneous closure of the left atrial appendage for secondary prevention of stroke in patients with atrial fibrillation and contraindications to chronic anticoagulant therapy
por: Lasek-Bal, Anetta, et al.
Publicado: (2015)

Stroke Prevention in Atrial Fibrillation: Focus on Asian Patients
por: Li, Yan-Guang, et al.
Publicado: (2018)

Risk of stroke or systemic embolism in patients with degenerative mitral stenosis with or without atrial fibrillation: A cohort study
por: Steiner, Daniel Kjærgaard, et al.
Publicado: (2022)

Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta-Analysis
por: Wang, Kang-Ling, et al.
Publicado: (2015)

Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation in secondary stroke and systemic embolism prevention
por: Gorczyca, Iwona, et al.
Publicado: (2019)

Aetiology, secondary prevention strategies and outcomes of ischaemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation
por: Polymeris, Alexandros A, et al.
Publicado: (2022)

Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios
por: Chang, Ting-Yung, et al.
Publicado: (2018)

Barriers to stroke prevention in Atrial Fibrillation: Insights from the global anticoagulation Roundtable
por: Barnes, Geoffrey D., et al.
Publicado: (2022)

Stroke prevention in atrial fibrillation: comparison of recent international guidelines
por: Chao, Tze-Fan, et al.
Publicado: (2020)

Erratum to: NOACs for secondary stroke prevention in patients with atrial fibrillation
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jcio1u70nl1dohrn1gt23v9dv6